Biocon Limited has announced the launch of its Glucagon-like Peptide-1 (GLP-1), Liraglutide, for diabetes and obesity in the Netherlands through Pharmamedic B.V. The drug-device combination will be marketed under the brand names Diavorin® and Vobexoryn®. This launch follows approval from the Medicines Evaluation Board (MEB) and marks the first country in the European Union where Biocon will directly launch Liraglutide under its brand.
Liraglutide Launch Details
Biocon Limited (BSE code: 532523, NSE: BIOCON) has launched its GLP-1 peptide, Liraglutide, in the Netherlands. The drug is intended for both diabetes (gVictoza®) and obesity (gSaxenda®) treatments. The distribution will be handled by Pharmamedic B.V.
The drug-device combination will be available under the brand names Diavorin® for diabetes and Vobexoryn® for chronic weight management.
European Expansion
This launch is significant as it marks the first country in the European Union where Biocon will directly market Liraglutide under its own brand, following approval from the Medicines Evaluation Board (MEB) in the Netherlands earlier this year.
Executive Commentary
Siddharth Mittal, Chief Executive Officer and Managing Director of Biocon Limited, stated that the launch of Liraglutide in the Netherlands is a key milestone in expanding Biocon’s GLP-1 portfolio globally. He emphasized the company’s commitment to providing high-quality, affordable metabolic treatments at scale.
About Liraglutide
Liraglutide is a synthetic analog of GLP-1 peptide and is administered as a once-daily injection. It received approval for medical use in the European Union in 2009, and in the United States in 2010. It was later approved by the US FDA in 2014, and by the EMA a year later, for adults who are either obese or overweight with at least one weight-related condition.
Source: BSE
